3 Stocks With Recent Intensive Insider Selling

|
 |  Includes: CI, IOSP, NEWP
by: Markus Aarnio

There was intensive insider selling in Millennial Media (NYSE:MM) in October, 2012. The stock has been trending down since the intensive insider selling took place and is currently trading 50% below the October peak.

Click to enlarge

With this episode in mind, I screened for stocks which have seen recent intensive insider selling. Intensive insider selling can be defined by the following three criteria:

  1. The stock was sold by three or more insiders within one month.
  2. The stock was not purchased by any insiders in the month of intensive selling.
  3. At least two sellers decreased their holdings by more than 10%.

In this article, I will feature three stocks that met these three criteria of intensive insider selling in the last 30 days.

1. Innospec (NASDAQ:IOSP) develops, manufactures, blends, and markets fuel additives, personal care and fragrance products, and other specialty chemicals to oil refineries, personal care and fragrance companies, and other chemical and industrial companies worldwide.

Click to enlarge

Insider selling by insider (last 30 days)

  • Ian McRobbie sold 4,026 shares on February 26 - March 6, and currently holds 59,186 shares or 0.3% of the company. Ian McRobbie is Senior Vice President and Chief Technology Officer.
  • Brian Watt sold 1,860 shares on February 26, and currently holds 14,347 shares or less than 0.1% of the company. Brian Watt is Vice President, Strategic Planning and Regulatory Affairs.
  • Patrick Williams sold 27,765 shares on February 19-21, and currently holds 179,447 shares or 0.8% of the company. Patrick Williams is President and Chief Executive Officer.
  • Catherine Hessner sold 1,994 shares on February 19-26, and currently holds 33,237 shares or 0.1% of the company. Catherine Hessner is Senior Vice President Human Resources.
  • Ian Cleminson sold 17,879 shares on February 19-26, and currently holds 24,589 shares or 0.1% of the company. Ian Cleminson serves as Executive Vice President and Chief Financial Officer.
  • Mark Bracewell sold 1,260 shares on February 15, and currently holds 2,389 shares or less than 0.1% of the company. Mark Bracewell is Group Financial Controller.

Insider selling by calendar month

Here is a table of Innospec's insider trading activity by calendar month.

Month Insider selling / shares Insider buying / shares
March 2013 2,886 0
February 2013 51,898 0
January 2013 0 0
December 2012 0 0
November 2012 0 0
October 2012 0 0
September 2012 0 0
August 2012 16,464 0
July 2012 0 0
June 2012 0 0
May 2012 160,637 0
April 2012 0 0
March 2012 0 0
February 2012 0 0
Click to enlarge

The month of February 2013 has seen the most insider selling since May 2012.

Financials

The company reported the full-year 2012 financial results on February 12, with the following highlights:

Revenue $776.4 million
Net income $68.3 million
Cash $27.5 million
Debt $30.0 million
Click to enlarge

Competition

Innospec's competitors include BASF (OTCQX:BASFY) and NewMarket Corporation (NYSE:NEU). Here is a table comparing these companies.

Company IOSP BASFY NEU Industry Average (Specialty Chemicals)
Market Cap: 981.11M 88.56B 3.48B 5.56B
Employees: 900 107,775 1,710 6.80K
Qtrly Rev Growth (yoy): 0.07 0.09 0.02 0.09
Revenue: 776.40M 101.93B 2.22B 2.63B
Gross Margin: 0.31 0.26 0.29 0.34
EBITDA: 114.80M 16.25B 407.77M 354.00M
Operating Margin: 0.13 0.12 0.16 0.11
Net Income: 68.30M 6.32B 239.28M N/A
EPS: 2.86 6.88 17.85 1.01
P/E: 14.70 14.02 14.53 21.22
PEG (5 yr expected): 1.00 3.48 1.26 1.97
P/S: 1.26 0.87 1.57 1.39
Click to enlarge
Click to enlarge

Innospec's P/S ratio is in line with the industry average.

My analysis

There have been 11 insider sell transactions and there have not been any insider buy transactions during the last 30 days. There are two analyst buy ratings, zero neutral ratings and zero sell ratings, with an average target price of $40.67. The stock is trading at a P/E ratio of 14.70 and a forward P/E ratio of 10.87. The company has a book value of $13.58 per share. Before entering short this stock, I would like to get a bearish confirmation from the Point and Figure chart. The two main reasons for the proposed short entry are bearish analyst target prices and the intensive insider selling activity.

2. Cigna Corporation (NYSE:CI), a health services organization, provides insurance and related products and services in the United States and internationally.

Click to enlarge

Insider selling by insider (last 30 days)

  • William Zollars sold 854 shares on March 5, and currently holds 769 shares or less than 0.1% of the company. William Zollars has been a Director of Cigna since 2005.
  • Jane Henney sold 1,837 shares on March 5, and currently holds 769 shares or less than 0.1% of the company. Jane Henney has been a Director of Cigna since 2004.
  • Matthew Manders sold 14,733 shares on March 5, and currently holds 50,750 shares or less than 0.1% of the company. Matthew Manders is President of Regional and Operations.
  • David Cordani sold 49,650 shares on March 6, pursuant to a Rule 10b5-1 trading plan. David Cordani currently holds 50,750 shares or less than 0.1% of the company. David Cordani became President and Chief Executive Officer of Cigna Corporation in December 2009.
  • John Murabito sold 61,237 shares on March 5-6, and currently holds 119,573 shares or less than 0.1% of the company. John Murabito is Executive Vice President, Human Resources and Services.

Insider selling by calendar month

Here is a table of Cigna's insider trading activity by calendar month.

Month Insider selling / shares Insider buying / shares
March 2013 128,311 0
February 2013 0 0
January 2013 6,250 0
December 2012 0 0
November 2012 0 0
October 2012 18,966 0
September 2012 15,555 0
Click to enlarge

The month of March 2013 has seen the most insider selling.

Financials

The company reported the full year 2012 financial results on February 7, with the following highlights:

Revenue $29.1 billion
Net income $1.6 billion
Cash $3.1 billion
Debt $5.2 billion
Click to enlarge

Outlook

Cigna's outlook for full year 2013 consolidated adjusted income from operations is in the range of $1.70 billion to $1.83 billion, or $5.85 to $6.30 per share.

Competition

Cigna's competitors include Aetna (NYSE:AET), UnitedHealth Group (NYSE:UNH) and WellPoint (WLP). Here is a table comparing these companies.

Company CI AET UNH WLP Industry Average (Health Care Plans)
Market Cap: 16.85B 16.27B 55.14B 19.06B 17.01B
Employees: 35,800 35,000 133,000 43,500 30.22K
Qtrly Rev Growth (yoy): 0.41 0.16 0.11 0.01 0.09
Revenue: 29.12B 36.60B 110.62B 61.71B 29.12B
Gross Margin: 0.39 0.27 0.27 0.22 0.15
EBITDA: 3.22B 3.52B 10.15B 5.39B 3.22B
Operating Margin: 0.10 0.08 0.08 0.08 0.04
Net Income: 1.62B 1.66B 5.53B 2.66B N/A
EPS: 5.61 4.81 5.28 8.18 1.75
P/E: 10.51 10.31 10.19 7.67 33.18
PEG (5 yr expected): 0.94 1.15 0.88 0.66 1.45
P/S: 0.58 0.44 0.50 0.31 0.51
Click to enlarge
Click to enlarge

Cigna's P/S ratio is in line with the industry average.

My analysis

There have been five insider sell transactions and there have not been any insider buy transactions during the last 30 days. There are nine analyst buy ratings, three neutral ratings and zero sell ratings, with an average target price of $56.50. The stock is trading at a P/E ratio of 10.51 and a forward P/E ratio of 8.52. The company has a book value of $34.18 per share. Before entering short this stock, I would like to get a bearish confirmation from the Point and Figure chart. The two main reasons for the proposed short entry are bearish analyst target prices and the intensive insider selling activity.

3. Newport Corporation (NASDAQ:NEWP) and its subsidiaries provide technology products and systems to scientific research, microelectronics, aerospace and defense/security, life and health sciences, and industrial markets in the United States, Europe, and the Pacific Rim.

Click to enlarge

Insider selling by insider (last 30 days)

  • Charles Cargile sold 23,200 shares on February 26 - March 5, and currently holds 97,970 shares or 0.3% of the company. Charles Cargile is Senior Vice President and Chief Financial Officer.
  • Robert Phillippy sold 17,567 shares on February 12, pursuant to a Rule 10b5-1 trading plan. Robert Phillippy currently holds 169,471 shares or 0.4% of the company. Robert Phillippy is President & CEO of the company.
  • Jeffrey Coyne sold 8,000 shares on February 12, pursuant to a Rule 10b5-1 trading plan. Jeffrey Coyne currently holds 58,166 shares or 0.2% of the company. Jeffrey Coyne is Senior Vice President, General Counsel & Secretary.

Insider selling by calendar month

Here is a table of Newport's insider trading activity by calendar month.

Month Insider selling / shares Insider buying / shares
March 2013 13,200 0
February 2013 89,500 0
January 2013 24,950 0
December 2012 74,749 0
November 2012 0 0
October 2012 0 0
September 2012 0 0
August 2012 0 0
July 2012 0 0
June 2012 0 20,000
May 2012 0 0
April 2012 0 0
March 2012 19,960 0
February 2012 77,824 0
Click to enlarge

The month of February 2013 has seen the most insider selling since February 2012.

Financials

The company reported the full-year 2012 financial results on February 20 with the following highlights:

Revenue $595.3 million
Net loss $91.0 million
Cash $100.4 million
Debt $183.7 million
Click to enlarge

Outlook

Robert Phillippy, Newport's President and Chief Executive Officer, commented Newport's outlook for 2013 on February 20:

Over the past year we have integrated our recent acquisitions, improved operational efficiencies and increased our cash generation despite very challenging market conditions. Based on the input we have received from our customers, we expect market conditions to improve during the course of 2013 and our sales to increase in the second half of the year. However, we have not yet seen a meaningful increase in order activity, and based on our current backlog we expect our net sales in the first quarter of 2013 to be slightly lower on a sequential basis. Additionally, we expect our non-GAAP operating income and non-GAAP earnings per diluted share to decline sequentially in the first quarter, due to an increase in our operating expenses resulting from the seasonal nature of some expenses and continued investment to fund our growth initiatives. We expect the benefit of these investments, coupled with improved market conditions, to position us well to deliver solid financial results in 2013 and beyond.

Competition

Newport's competitors include Agilent Technologies (NYSE:A) and Corning (NYSE:GLW). Here is a table comparing these companies.

Company NEWP A GLW Industry Average (Industrial Equipment Wholesale)
Market Cap: 636.05M 15.01B 18.64B 4.42B
Employees: N/A 20,500 28,700 N/A
Qtrly Rev Growth (yoy): -0.12 0.03 0.14 0.00
Revenue: 595.35M 6.90B 8.01B 6.62B
Gross Margin : 0.44 0.52 0.42 0.37
EBITDA : 91.58M 1.40B 2.49B 681.79M
Operating Margin : 0.08 0.16 0.19 0.14
Net Income : -89.42M 1.10B 1.73B N/A
EPS : -2.35 3.13 1.15 1.96
P/E : N/A 13.82 11.01 13.12
PEG (5 yr expected): 1.56 1.73 0.89 0.67
P/S : 1.07 2.17 2.33 1.66
Click to enlarge
Click to enlarge

Newport is trading below the industry average P/S ratio.

My analysis

There have been four insider sell transactions and there have not been any insider buy transactions during the last 30 days. The stock is trading at a forward P/E ratio of 12.12. The company has a book value of $10.41 per share. Before entering short this stock, I would like to get a bearish confirmation from the Point and Figure chart. The two main reasons for the proposed short entry are weak first-quarter outlook and the intensive insider selling activity.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.